Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility

被引：144

作者：

Katiyar, Santosh

Pfaller, Michael

Edlind, Thomas

机构：

[1] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA

[2] Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 08期

关键词：

D O I：

10.1128/AAC.00349-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A recognized hotspot for mutations conferring reduced echinocandin susceptibility (RES) is residue S645 of Candida albicans Gsc1(Fks1). We report that the mutation F641Y is associated with RES in a C albicans isolate. The analogous Fks2 residue is mutated F to V in a Candida glabrata RES isolate; the introduction of this mutation into susceptible C glabrata confirmed its role in RES. Y641-equivalent Fks residues were identified in intrinsically RES Fusarium species and Candida guilliermondii.

引用

页码：2892 / 2894

页数：3

共 22 条

[1] Echinocandin antifungal drugs [J].

Denning, DW .

LANCET, 2003, 362 (9390) :1142-1151

[2]

Douglas CM, 2001, MED MYCOL, V39, P55, DOI 10.1080/mmy.39.1.55.66

[3] Genome evolution in yeasts [J].

Dujon, B ;

Sherman, D ;

Fischer, G ;

Durrens, P ;

Casaregola, S ;

Lafontaine, I ;

de Montigny, J ;

Marck, C ;

Neuvéglise, C ;

Talla, E ;

Goffard, N ;

Frangeul, L ;

Aigle, M ;

Anthouard, V ;

Babour, A ;

Barbe, V ;

Barnay, S ;

Blanchin, S ;

Beckerich, JM ;

Beyne, E ;

Bleykasten, C ;

Boisramé, A ;

Boyer, J ;

Cattolico, L ;

Confanioleri, F ;

de Daruvar, A ;

Despons, L ;

Fabre, E ;

Fairhead, C ;

Ferry-Dumazet, H ;

Groppi, A ;

Hantraye, F ;

Hennequin, C ;

Jauniaux, N ;

Joyet, P ;

Kachouri, R ;

Kerrest, A ;

Koszul, R ;

Lemaire, M ;

Lesur, I ;

Ma, L ;

Muller, H ;

Nicaud, JM ;

Nikolski, M ;

Oztas, S ;

Ozier-Kalogeropoulos, O ;

Pellenz, S ;

Potier, S ;

Richard, GF ;

Straub, ML .

NATURE, 2004, 430 (6995) :35-44

[4] Promoter-dependent disruption of genes: simple, rapid, and specific PCR-based method with application to three different yeast [J].

Edlind, TD ;

Henry, KW ;

Vermitsky, JP ;

Edlind, MP ;

Raj, S ;

Katiyar, SK .

CURRENT GENETICS, 2005, 48 (02) :117-125

[5] Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].

Espinel-Ingroff, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956

[6] Caspofungin resistance in Candida albicans:: Correlating clinical outcome with laboratory susceptibility testing of three is genic isolates serially obtained from a patient with progressive candida esophagitis [J].

Hernandez, S ;

López-Ribot, JL ;

Najvar, LK ;

McCarthy, DI ;

Bocanegra, R ;

Graybill, JR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1382-1383

[7] Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient [J].

Krogh-Madsen, M ;

Arendrup, MC ;

Heslet, L ;

Knudsen, JD .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (07) :938-944

[8]

Kurtz MB, 2001, ADV PROTEIN CHEM, V56, P423

[9] Characterization of echinocardin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies [J].

Kurtz, MB ;

Abruzzo, G ;

Bartizal, K ;

Marrinan, JA ;

Li, W ;

Milligan, J ;

Nollstadt, K ;

Douglas, CM .

INFECTION AND IMMUNITY, 1996, 64 (08) :3244-3251

[10] Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis [J].

Laverdière, M ;

Lalonde, RG ;

Baril, JG ;

Sheppard, DC ;

Park, S ;

Perlin, DS .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :705-708

← 1 2 3 →